AI Article Synopsis
- The study aimed to assess vaginal toxicity and local control in patients with endometrial cancer undergoing surgery followed by high-dose-rate endovaginal brachytherapy.
- The authors conducted a systematic review of various studies published over a 20-year period, analyzing outcomes from a range of clinical trials and case studies.
- Results showed that acute vaginal toxicity was low, with less than 20.6% of patients experiencing side effects, and late toxicities were also minimal; this indicates that HDR brachytherapy is generally well-tolerated, although additional research is needed for better patient evaluation.
Article Abstract
Purpose: To evaluate vaginal toxicity (primary endpoint) and local control (secondary endpoint) in patients with endometrial cancer who underwent primary surgery and adjuvant high-dose-rate (HDR) endovaginal brachytherapy (BT).
Material And Methods: In September 2017, the authors conducted a comprehensive literature search of the following electronic databases: PubMed, Web of Science, Scopus, and Cochrane library. In this systematic review, the authors included randomized trials, non-randomized trials, prospective studies, retrospective studies, and cases. The time period of the research included articles published from September 1997 to September 2017.
Results: Acute endovaginal toxicity occurred in less than 20.6% and all acute toxicities were G1-G2. The most common early side effects due to HDR-BT treatment were vaginal inflammation, vaginal irritation, dryness, discharge, soreness, swelling, and fungal infection. G1-G2 late toxicity occurred in less than 27.7%. Finally, G3-G4 late vaginal occurred in less than 2%. The most common late side effects consisted of vaginal discharge, dryness, itching, bleeding, fibrosis, telangiectasias, stenosis, short or narrow vagina, and dyspareunia.
Conclusions: The data suggest that HDR endovaginal brachytherapy, with or without chemotherapy, is very well tolerated with low rates of acute and late vaginal toxicities. Further prospective studies with higher numbers of patients and longer follow-up are necessary to evaluate acute and late toxicities after HDR endovaginal brachytherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335557 | PMC |
| http://dx.doi.org/10.5114/jcb.2018.79713 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Impact of HAPPY (Humanity Assurance Protocol in Interventional Radiotherapy) on the Psychological Well-being of Gynecological Cancer Patients.
Curr Radiopharm
July 2024
Dipartimento di Diagnostica per Immagini, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC Radioterapia Oncologica, Radioterapia Oncologica ed Ematologia, 00168, Rome, Italy.
Background: HAPPY (Humanity Assurance Protocol in Interventional Radiotherapy) reports the necessity for gynecological cancer patients to undergo interventional radiotherapy (IRT, also called brachytherapy). The present paper has evaluated how some precautions may improve the psychological well-being of the patients during IRT.
Methods: Patients with gynecological cancer undergoing IRT-HDR were analyzed.
Radiotherapy for Vaginal Recurrences of Cervical Cancer in Patients After Prior Surgery: Analysis of Effect and Prognostic Factors.
Front Oncol
September 2021
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Objective: The role of salvage radiotherapy (RT) in the treatment for vaginal recurrence of cervical cancer in patients after prior surgery remains controversial. The aim of this study was to evaluate the efficacy and toxicity of salvage RT and explore prognostic factors associated with the survival after recurrence.
Methods: Patients with cervical cancer, treated for vaginal recurrences at Peking Union Medical College Hospital between July 2011 and November 2019, were identified.
An endovaginal MRI array with a forward-looking coil for advanced gynecological cancer brachytherapy procedures: Design and initial results.
Med Phys
November 2021
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Purpose: To develop an endovaginal MRI array that provides signal enhancement forward into the posterior parametrium and sideways into the vaginal wall, accelerating multiple-contrast detection of residual tumors that survive external beam radiation. The array's enclosure should form an obturator for cervical cancer brachytherapy, allowing integration with MRI-guided catheter placement, CT, and interstitial radiation dose delivery.
Methods: The endovaginal array consisted of forward-looking and sideways-looking components.
HAPPY - Humanity Assurance Protocol in interventional radiotheraPY (brachytherapy) - an AIRO Interventional Radiotherapy Study Group project.
J Contemp Brachytherapy
December 2019
UOC Radioterapia Oncologica, Dipartimento di Diagnostica per immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Purpose: Interventional procedures may produce emotional distress, particularly in interventional radiotherapy (IRT, brachytherapy - BT). This work would like to propose a series of recommendationsinterventions to guarantee a human approach in order to favor the psychological well-being of the patient during interventional radiotherapy.
Material And Methods: Thirty patients affected by gynecological cancer and treated with endovaginal high-dose-rate IRT (HDR-IRT) were selected from January to March 2019.
Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results.
J Contemp Brachytherapy
December 2018
Department of Radiotherapy, Alessandro Manzoni Hospital, Lecco.
Article Synopsis
- The study aimed to assess vaginal toxicity and local control in patients with endometrial cancer undergoing surgery followed by high-dose-rate endovaginal brachytherapy.
- The authors conducted a systematic review of various studies published over a 20-year period, analyzing outcomes from a range of clinical trials and case studies.
- Results showed that acute vaginal toxicity was low, with less than 20.6% of patients experiencing side effects, and late toxicities were also minimal; this indicates that HDR brachytherapy is generally well-tolerated, although additional research is needed for better patient evaluation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!